ARS Pharmaceuticals Stock (NASDAQ:SPRY)
Previous Close
$11.32
52W Range
$5.10 - $18.51
50D Avg
$14.42
200D Avg
$11.42
Market Cap
$1.09B
Avg Vol (3M)
$1.06M
Beta
1.00
Div Yield
-
SPRY Company Profile
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |
| TCRX | TScan Therapeutics, Inc. |
| ANNX | Annexon, Inc. |
| WVE | Wave Life Sciences Ltd. |
| IMMX | Immix Biopharma, Inc. |
| ALLR | Allarity Therapeutics, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| WINT | Windtree Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| CGTX | Cognition Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| PALI | Palisade Bio, Inc. |